Day: September 26, 2025

BEIJING, China, Sept. 26, 2025 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today officially launched Li i6, a pioneering five-seat battery electric SUV. Li i6 is priced at RMB249,800 for its standard configuration. Deliveries of Li i6 will commence on September 27, 2025. For more details on Li i6, please visit Li Auto’s official website. About Li Auto Inc. Li Auto Inc. is a leader in China’s new energy vehicle market. The Company designs, develops, manufactures, and sells premium smart electric vehicles. Its mission is: Create a Mobile Home, Create Happiness (创造移动的家,创造幸福的家). Through innovations in product, technology, and business model, the Company provides families with safe, convenient, and comfortable products and services. Li Auto is...

Now Operating in 19 States Nationwide Las Vegas, NV, Sept. 26, 2025 (GLOBE NEWSWIRE) —Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide Mesquite, NV — September 26, 2025 — Dogecoin Cash, Inc. (OTCQB: DOGP today announced that its subsidiary PrestoDoctor, a leading telemedicine platform for medical cannabis evaluations, is expanding services to Connecticut. With this addition, PrestoDoctor now operates in 19 states across the United States, further extending the Company’s decade-long track record of helping patients access medical cannabis care through secure and compliant telehealth. Since launching in 2015, PrestoDoctor has provided care to over 500,000 patients nationwide, building one of the most established and trusted platforms for medical cannabis telehealth services. Over ten years of continuous...

Premium Income (insurance premiums and other income) of €12.9 billion, up +7.1%Growth in Property and Casualty Insurance (+6.4%) Increase in premium income in Health and Protection insurance (+7.3%) Growth in the Savings &Pensions business (+9.1%) Insurance revenue (IFRS 17) of €8.3 billionNet Income of €450 million, up +13%Economic operating income of €503 million, up +23% Major weather events, including Cyclone Garance on Reunion Island in February and severe storms in June in metropolitan France Combined ratio of 94.1%Strong Solvency Ratio of 211% without transitional measures Solvency ratio of 263% with the transitional measure on technical provisions Equity of €11.0 billion Contractual services margin of €4.1 billionThe Board of Directors of Groupama Assurances Mutuelles met on 25 September 2025, under the chairmanship...

September 26, 2025News Release BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented COPENHAGEN, DENMARK and BOSTON, MA, USA, September 26 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), is pleased to support conferences focused on pediatric solid organ transplants and critical care nephrology. Clinical researchers present posters, abstracts and new publications using NGAL in their patients, leading to better identification for risk of Acute Kidney Injury (AKI) and management of the patient’s journey and clinical decision making. International Pediatric Transplant Association (IPTA) meets every 2 years for surgeons, nephrologists, hepatologists, and critical care clinicians. Berlin hosted an event with over 500 participants with tracks for liver, heart and kidney transplant topics....

SHANGHAI, Sept. 26, 2025 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in AI-driven Internet healthcare solutions, announced that its “XingShi” Large Language Model (“XS LLM”) was featured by Nature News under the headline “A Chinese AI tool can manage chronic disease — could it revolutionize health care?” The article, written by science reporter Mohana Basu, cited the model’s potential applications for chronic disease management, while citing expert commentary. Xinhua News Agency also highlighted the piece under the headline “Nature focuses on Fangzhou’s XS LLM: Chinese AI tackling global chronic disease challenges.” This recognition underscores the growing role of AI in addressing global health issues. Fangzhou’s XS LLM, released in September, was designed to address...

(Oslo/Bergen 26 September 2025) Statkraft and Eviny have signed an agreement with Nepalese local partner Butwal Power Company (BPC) to sell their 57 and 26 percent shareholdings in Himal Power Limited (HPL). With this transaction, BPC will own 100 percent of the shares in HPL.  HPL owns the 60 MW Khimti I Hydropower Plant which started operations in 2000. This initiative is consistent with Statkraft’s strategy of exiting South Asia and focusing on key markets in Europe and South America. The construction of the Khimti I Hydropower Plant in Nepal was Statkraft’s first hydropower development outside Norway.  “Statkraft and Eviny are proud of the important contribution the Khimti plant has made to the Nepalese energy system for 25 years, delivering more than 9,000 GWh of energy with an excellent operational record and world class availability....

Reserve Bank of India (RBI) has approved biometric authentication technology for digital payments, including IDEX’s fingerprint payment solutions, through new authentication mechanisms for digital payment transactions directions effective April 2026. The RBI mandate specifically endorses fingerprint biometric authentication as an approved method for India’s digital payment ecosystem, moving beyond traditional SMS-based one-time passwords. This regulatory approval validates IDEX’s strategic positioning in the Indian market. Anders Storbråten, CEO of IDEX Biometrics, highlighted the strategic significance: “The RBI’s approval of biometric authentication represents a transformational moment for digital payment security in India. IDEX has been strategically positioned for this regulatory shift, having successfully...

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured from U.S. donors in the U.S. and designated as U.S. origin products not subject to tariffs on imported branded or patented pharmaceutical products. Ryoncil® (remestemcel-L) is the only allogeneic mesenchymal stromal cell therapy approved by U.S. Food and Drug Administration (FDA) for any indication. As documented in the Company’s Biologic License Application (BLA), Ryoncil® is designated a ‘U.S. Country of Origin’ product in line with U.S. FDA and Customs regulatory guidance. Ryoncil® is approved for treatment of pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory...

Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPCNATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient populationNew data for Pluvicto in prostate cancer and Kisqali in breast cancer strengthen the profiles of both medicines, with promise for new SoC in earlier disease settingsBasel, September 26, 2025 – Novartis will present new data from 34 abstracts across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin (October 17-21, 2025). “We look forward to sharing new clinical data that underscores how we are reimagining treatment for breast and prostate cancer, advancing...